MGF, short for mechano growth factor, is the name given to a splice variant of insulin-like growth factor 1 that muscle produces locally in response to mechanical load or damage. The load-responsive biology of the endogenous variant is documented in physiology research; the injectable performance and recovery claims attached to the synthetic version are not established by controlled human trials, and the two sit at very different levels of evidence.
MGF is the IGF-1Ec splice variant of IGF-1, produced in skeletal muscle when retention of exon 5 adds a C-terminal E-domain, and its documented role is local, load-induced muscle adaptation rather than any approved human therapy.
The distinction between MGF and systemic IGF-1 is one of splicing, source, and reach, not a separate gene. Both come from the same IGF-1 gene, but retention of exon 5 in the MGF transcript introduces a reading-frame shift that adds the unique E-domain, and the two isoforms then behave differently: circulating IGF-1 is a slow, whole-body endocrine signal, while MGF is expressed transiently inside working or damaged muscle and acts on nearby cells.
| Property | MGF (IGF-1Ec) | Systemic IGF-1 |
|---|---|---|
| Primary source | Local skeletal muscle under mechanical load | Liver, under growth hormone stimulation |
| Splice pattern | Exon 5 retained, adding the E-domain | Mature IGF-1 sequence, no E-domain |
| Reach | Autocrine and paracrine, on-site | Endocrine, body-wide |
| Timing | Transient, load-responsive | Slow, sustained |
MGF and systemic IGF-1 are transcribed from the same IGF-1 gene, but MGF's retention of exon 5 produces the E-domain-bearing IGF-1Ec isoform that acts locally in muscle, whereas the liver-derived mature peptide circulates as a body-wide endocrine hormone.
MGF expression is stimulus-driven, and the triggering stimulus is mechanical strain on the muscle fiber: resistance exercise, stretch, eccentric loading, and frank damage all push the IGF-1 gene toward the exon-5-retaining splice. The response is fast and transient, which supports the model of MGF as an early alarm signal that opens the repair program before the slower systemic IGF-1 rise takes over.
The IGF-1Ec transcript spikes within hours of acute resistance exercise and then subsides, and the magnitude of that load-induced response is generally reported to be blunted in older muscle.
The most distinctive claim about MGF is that its C-terminal E-domain has activity that does not run through the classical IGF-1 receptor, which is what makes the variant more than a local copy of IGF-1. When the IGF-1Ec propeptide is processed, the E-domain can be liberated as a short peptide, and laboratory work on that isolated fragment has reported effects on muscle precursor cells in conditions where the IGF-1 receptor pathway does not appear to be the mediator. The honest limitation is that the receptor responsible for that standalone effect has not been identified, so the pathway is described functionally rather than molecularly.
The isolated E-domain peptide has shown proliferation-promoting, differentiation-delaying effects on muscle precursor cells in models where the IGF-1 receptor is not the apparent mediator, but no specific receptor for that standalone activity has been definitively identified.
Repair of adult skeletal muscle depends on satellite cells, the stem-cell population that stays quiescent beneath the basal lamina until injury or overload activates it, and the proposed role of MGF sits right at that wake-up step. The evidence here is strongest at the cell and animal level: the satellite-cell activation is supported in laboratory models, which is not the same as a dose-controlled hypertrophy effect from an injected peptide in people.
Satellite-cell proliferation and fusion, which add new myonuclei to a fiber, are established mechanisms of muscle repair and growth, and MGF's proposed contribution is to help drive the early proliferative expansion of that satellite-cell pool, a role supported in laboratory and animal models rather than by controlled human trials.
The synthetic product sold as MGF is usually the isolated E-domain peptide, not the complete IGF-1Ec molecule that muscle makes, and that gap drives every meaningful difference. Endogenous MGF is generated inside the fiber, presented locally, and cleared quickly; a vial reverses those properties, delivering a fragment from outside the cell, all at once, with none of the native spatial or temporal precision, and often as a stabilized or pegylated analogue further removed from the natural molecule.
| Property | Endogenous MGF | Synthetic E-domain peptide |
|---|---|---|
| Molecule | Complete IGF-1Ec propeptide | Isolated E-domain fragment only |
| Origin | Made inside the muscle fiber | Delivered from outside the cell |
| Delivery | Local, precisely timed | Bolus, wherever injection or blood carries it |
| Persistence | Very short-lived by design | Often engineered to resist degradation |
| IGF-1R binding | Retains the receptor-binding portion | Omits it, cannot reproduce the dual action |
Synthetic MGF is typically the isolated E-domain fragment delivered as an external bolus and frequently stabilized against degradation, so it omits the IGF-1 receptor-binding portion of the intact propeptide and cannot reproduce the locally timed dual action of endogenous MGF, and controlled human evidence for its product-level benefits is not established.
MGF's signaling is best read as two loosely coupled stories, one solid and one unfinished. The solid one runs through the IGF-1 domain MGF shares with mature IGF-1; the unfinished one is the receptor-independent E-domain effect, which does not fit cleanly with IGF-1 receptor activation and lacks an identified receptor of its own.
To the extent MGF acts through the IGF-1 receptor it drives the well-characterized PI3K-Akt-mTOR and Ras-MAPK cascades, while the distinctive receptor-independent E-domain effects have no firmly identified receptor and remain defined by their cellular outputs rather than a mapped molecular route.
Stability is one of the more consistently emphasized features of native MGF: it is short-lived, which fits its design as a local autocrine and paracrine signal meant to fire briefly in stressed tissue and then stand down. That short persistence is part of why MGF is not treated as a systemic hormone the way liver-derived IGF-1 is, and precise in vivo half-life numbers are not something the literature agrees on, since values depend on the exact sequence, whether it is native or stabilized, the model, and the route.
Native MGF is short-lived and locally cleared by design, which is why it functions as a transient on-site signal rather than a systemic hormone, and no single agreed in vivo half-life figure exists because reported values depend on sequence, stabilization, model system, and route of delivery.
Synthetic MGF holds a research-chemical status, not a medicine status, and the two should not be blurred. It is distributed research-use-only as a laboratory reagent, has not passed the approval process that would establish safety, efficacy, dosing, and manufacturing standards, and carries no sanctioned human indication; the research-use-only label is a distribution category, not a certification of purity, safety, or fitness for human administration.
Synthetic MGF is sold research-use-only as a laboratory reagent with no drug-regulator approval and no sanctioned human indication, and because IGF-1-family growth factors are prohibited in sport, its use by competitive athletes carries anti-doping sanction risk on top of its unapproved status.
Educational use only. This article describes what the published scientific and clinical literature reports about MGF (mechano growth factor). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
